Buscar
Mostrando ítems 21-26 de 26
Tesis Doctoral
Immune Biomarkers In Peripheral Blood In Patients With HER2 Negative Advanced Breast Cancer Treated With A Chemoimmunotherapy Schedule Based On Pembrolizumab And Gemcitabine. – Translational Substudy Of The PANGEA- Breast Cancer Trial (GEICAM/2015-04)
(2022-03-31)
Within the last years, immune checkpoint inhibitors (ICI) have constituted a major breakthrough in cancer research. These molecules are monoclonal antibodies (mAb) with immunomodulatory properties as they target specific ...
Artículo
New horizons in breast cancer: the promise of immunotherapy
(Springer, 2019)
Immunology and immunotherapy of cancer is an expanding feld in oncology, with recent great achievements obtained through the new successful approaches implemented to circumvent immune evasion, which is undoubtedly ...
Artículo
New insights into the role of the immune microenvironment in breast carcinoma
(2013)
Recently, immune edition has been recognized as a new hallmark of cancer. In this respect, some clinical trials in breast cancer have reported imppressive outcomes related to laboratory immune findings, especially in the ...
Artículo
Circulating immune biomarkers in peripheral blood correlate with clinical outcomes in advanced breast cancer
(Nature publishing group, 2021)
Identifcation of the diferent elements intervening at the tumor microenvironment seems key to explain clinical evolution in several tumor types. In this study, a set of immune biomarkers (myeloid derived suppressor ...
Artículo
Integrating the tumor microenvironment into cancer therapy
(MDPI, 2020)
Tumor progression is mediated by reciprocal interaction between tumor cells and their surrounding tumor microenvironment (TME), which among other factors encompasses the extracellular milieu, immune cells, fibroblasts, and ...
Artículo
Pembrolizumab Plus Gemcitabine in the Subset of Triple-Negative Advanced Breast Cancer Patients in the GEICAM/2015-04 (PANGEA-Breast) Study
(MDPI, 2021-10-29)
The PANGEA-Breast trial evaluated a new chemo-immunotherapeutic combination that would synergistically induce long-term clinical benefit in HER2-negative advanced breast cancer patients. Treatment consisted of 21-day cycles ...